Beijing Hengruikangda Pharmaceutical Technology Development

Beijing Hengruikangda Pharmaceutical Technology Development is a key R&D subsidiary of Jiangsu Hengrui Pharmaceuticals, one of China's largest and most innovative pharmaceutical companies. Based in Beijing's Zhongguancun Life Science Park, the company focuses on the discovery and early-stage development of novel small molecules and biologics. Its research efforts are primarily directed toward oncology, metabolic diseases, and autoimmune disorders, contributing significantly to the parent company's robust pipeline. The entity plays a crucial role in advancing candidates through the IND-enabling phase and supporting clinical trials within the Chinese regulatory framework. By leveraging advanced technology platforms such as antibody-drug conjugates and proteolysis-targeting chimeras, Beijing Hengruikangda helps maintain Hengrui's leadership in the domestic market. The company is integral to the group's global strategy, facilitating collaborations and ensuring a steady stream of innovative therapies for patients worldwide.